A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/50 (2006.01) A61K 9/16 (2006.01) A61K 31/44 (2006.01) A61K 47/36 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2758820
A targeted sustained-release microsphere vascular embolizing agent, the production method and the use thereof are disclosed. The microsphere comprises sodium alginate as the carrier and sorafenib as the targeted anti-tumor medicine and sorafenib is encapsulated by sodium alginate. The weight ratio of sorafenib to sodium alginate is 1:1-1:30. The microspheres are used for manufacturing medicament for the treatment of solid tumors with advantages including high medicine concentration in the target regions with reduced systemic dosage and toxic and side effects.
La présente invention concerne une microsphère à libération prolongée ciblée d'un agent d'occlusion vasculaire, sa méthode de production et son utilisation. Ladite microsphère comprend de l'alginate de sodium en tant que support et du sorafénib en tant que médicament antitumoral ciblé, le sorafénib étant recouvert d'alginate de sodium. Le rapport pondéral du sorafénib sur l'alginate de sodium est de 1/1 à 1/30. Ladite microsphère est utilisée pour la préparation d'un médicament destiné au traitement d'une tumeur solide et pour une concentration élevée du médicament dans les régions cibles avec un dosage réduit et une hypotoxicité.
Hong Hong
Li Xinjian
Lu Ge
Beijing Shengyiyao Science & Technology Development Co. Ltd
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Targeted sustained-release microsphere of vascular occlusive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted sustained-release microsphere of vascular occlusive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted sustained-release microsphere of vascular occlusive... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1716060